Dimensional Fund Advisors LP Decreases Position in AnaptysBio, Inc. (NASDAQ:ANAB)

Dimensional Fund Advisors LP decreased its holdings in shares of AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) by 67.1% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 31,608 shares of the biotechnology company's stock after selling 64,364 shares during the quarter. Dimensional Fund Advisors LP owned 0.10% of AnaptysBio worth $418,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of the business. KLP Kapitalforvaltning AS bought a new position in AnaptysBio in the fourth quarter worth approximately $40,000. AlphaQuest LLC grew its stake in AnaptysBio by 1,891.5% in the fourth quarter. AlphaQuest LLC now owns 4,461 shares of the biotechnology company's stock worth $59,000 after purchasing an additional 4,237 shares in the last quarter. Russell Investments Group Ltd. grew its stake in AnaptysBio by 1,585.8% in the fourth quarter. Russell Investments Group Ltd. now owns 5,698 shares of the biotechnology company's stock worth $75,000 after purchasing an additional 5,360 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its stake in AnaptysBio by 11.1% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 6,452 shares of the biotechnology company's stock worth $85,000 after purchasing an additional 644 shares in the last quarter. Finally, Aristides Capital LLC bought a new position in AnaptysBio in the fourth quarter worth approximately $168,000.

AnaptysBio Stock Performance

AnaptysBio stock traded down $0.07 during mid-day trading on Thursday, reaching $20.74. 360,420 shares of the company were exchanged, compared to its average volume of 600,622. The business has a fifty day moving average of $19.28 and a 200 day moving average of $18.28. The firm has a market cap of $609.34 million, a P/E ratio of -3.41 and a beta of -0.20. AnaptysBio, Inc. has a 12-month low of $12.21 and a 12-month high of $41.31.

AnaptysBio (NASDAQ:ANAB - Get Free Report) last issued its quarterly earnings data on Monday, May 5th. The biotechnology company reported ($1.28) EPS for the quarter, beating the consensus estimate of ($1.30) by $0.02. AnaptysBio had a negative return on equity of 287.94% and a negative net margin of 289.75%. The firm had revenue of $27.77 million during the quarter, compared to analyst estimates of $15.27 million. Sell-side analysts predict that AnaptysBio, Inc. will post -6.08 EPS for the current year.

AnaptysBio announced that its Board of Directors has approved a stock repurchase plan on Monday, March 24th that allows the company to buyback $75.00 million in shares. This buyback authorization allows the biotechnology company to buy up to 13.1% of its stock through open market purchases. Stock buyback plans are generally an indication that the company's management believes its stock is undervalued.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on the company. Wells Fargo & Company increased their price objective on AnaptysBio from $40.00 to $51.00 and gave the stock an "overweight" rating in a research note on Thursday, February 13th. Johnson Rice reissued a "buy" rating on shares of AnaptysBio in a research note on Wednesday, March 26th. Guggenheim increased their price objective on AnaptysBio from $52.00 to $54.00 and gave the stock a "buy" rating in a research note on Tuesday, May 6th. HC Wainwright restated a "neutral" rating and set a $22.00 target price on shares of AnaptysBio in a report on Tuesday, March 4th. Finally, Wolfe Research initiated coverage on AnaptysBio in a report on Tuesday, February 4th. They set an "outperform" rating and a $25.00 target price for the company. Four investment analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $35.88.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.